Dr. Lawrence Blonde, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
1514 Jefferson Hwy
New Orleans, LA 70121
Who else practices at this address →
Jefferson Parish includes primary care (18% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
LA license MD.03383R
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 6 payments worth $11,233 in total to this clinician.
| Novo Nordisk Inc | $11,233 |
|---|
| Consulting Fee | $9,416 |
|---|---|
| Travel and Lodging | $1,517 |
| Food and Beverage | $300 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Apr 23, 2025 | Consulting Fee Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,486 |
| Novo Nordisk Inc Apr 22, 2025 | Consulting Fee Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $930 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $608 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $470 |
| Novo Nordisk Inc Apr 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Coral Gables, FL · in-kind | $439 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,037 in research payments for these studies, mostly to the institutions running them.
- BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study.
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.